Elif Aral, country manager of Pfizer Turkey, stresses that Turkey will continue to be perceived as essential and important, where healthcare is a top priority with its young but aging population. In addition, as the newly appointed Chairman of the Board of Directors of the Association of Research-Based Pharmaceutical Companies (AiFD), she highlights how the association aims to work hand in hand with the new government to entrench Turkey’s position as a globally competitive market and ecosystem for the pharmaceutical industry.
As you have been recently appointed Chairman of the AiFD, what are your priorities?
“Overall, the commitment of Pfizer to Turkey is already remarkable: 75 percent of our products consumed in the country are already locally manufactured, while Pfizer’s flagship vaccine Prevnar 13® has been manufactured in Turkey with formulation, filling and packaging phases since 2012. "
